ADAM CARTER: Open Payments
NPI 1174014237 · TEMPE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$545 in 27 payments from 11 companies in 2025. Trend: 2023 $1,015 · 2024 $794 · 2025 $545
Food & beverage: $545
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 6 | $109 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Supernus Pharmaceuticals, Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Boston Scientific Corporation | 1 | $39 |
| Alkermes, Inc. | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| Bausch Health US, LLC | 1 | $20 |
Products named: REXULTI, Qelbree, CAPLYTA, TRINTELLIX, General - BPH, LYBALVI, FANAPT, ABILIFY ASIMTUFII.
Industry payments across AZ — which companies pay providers there.
